Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

TransMedics (TMDX) EBITDA (2018 - 2025)

Historic EBITDA for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $23.3 million.

  • TransMedics' EBITDA rose 49393.32% to $23.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.0 million, marking a year-over-year increase of 20505.17%. This contributed to the annual value of $37.5 million for FY2024, which is 23052.53% up from last year.
  • Per TransMedics' latest filing, its EBITDA stood at $23.3 million for Q3 2025, which was up 49393.32% from $36.6 million recorded in Q2 2025.
  • TransMedics' 5-year EBITDA high stood at $36.6 million for Q2 2025, and its period low was -$28.3 million during Q3 2023.
  • In the last 5 years, TransMedics' EBITDA had a median value of -$2.1 million in 2023 and averaged $1.3 million.
  • Per our database at Business Quant, TransMedics' EBITDA crashed by 41109.31% in 2023 and then skyrocketed by 148057.4% in 2024.
  • Over the past 5 years, TransMedics' EBITDA (Quarter) stood at -$11.3 million in 2021, then soared by 40.16% to -$6.8 million in 2022, then soared by 138.4% to $2.6 million in 2023, then soared by 232.08% to $8.6 million in 2024, then soared by 169.55% to $23.3 million in 2025.
  • Its EBITDA stands at $23.3 million for Q3 2025, versus $36.6 million for Q2 2025 and $27.4 million for Q1 2025.